Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy

References

• Dooley MA, Aranow C, Ginzler EM. Review of ACR renal criteria in systemic lupus erythematosus. Lupus 2004; 13(11):857–60.
   PubMed Web of Science ®Google Scholar
• Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al; European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82(5):299–308.
   PubMed Web of Science ®Google Scholar
• Moroni G, Quaglini S, Gallelli B, Banfi G, Messa P, Ponticelli C. Progressive improvement of patient and renal survival and reduction of morbidity over time in patients with lupus nephritis (LN) followed for 20 years. Lupus. 2013;22(8):810–8.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Yamamoto K, Takeuchi T, Nishimoto N, Miyasaka N, Sumida T, et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol. 2007;17(3):191–7.
   PubMedGoogle Scholar
• Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002;46:2673–7.
   PubMed Web of Science ®Google Scholar
• Lu TY, Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum. 2009;61(4):482–7.
   PubMed Web of Science ®Google Scholar
• Jonsdottir T, Gunnarsson I, Mourao AF, Lu TY, van Vollenhoven RF, Isenberg D. Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts. Rheumatology (Oxford). 2010;49(8):1502–4.
   PubMed Web of Science ®Google Scholar
• Melander C, Sallee M, Trolliet P, Candon S, Belenfant X, Daugas E, et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-erm renal outcome. Clin J Am Soc Nephrol. 2009;4(3):579–87.
   PubMed Web of Science ®Google Scholar
• Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222–33.
   PubMed Web of Science ®Google Scholar
• Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum. 2012;64(4):1215–26.
   PubMed Web of Science ®Google Scholar
• Tew GW, Rabbee N, Wolslegel K, Hsieh H-J, Monroe JG, et al. Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus. Lupus. 2010;19(2):146–57.
   PubMed Web of Science ®Google Scholar
• Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012;64(6):797–808.
   PubMed Web of Science ®Google Scholar
• Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JHM, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–82.
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40(9):1725.
   PubMed Web of Science ®Google Scholar
• Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med. 1993;86(7):447–58.
   PubMedGoogle Scholar
• Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum. 2006;54(2): 421–32.
   PubMed Web of Science ®Google Scholar
• Markowitz GS, D’Agati VD. The ISN/RPS 2003 classification of lupus nephritis: an assessment at 3 years. Kidney Int. 2007;71(6):491–5.
   PubMed Web of Science ®Google Scholar
• Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2010;62(8):2458–66.
   PubMed Web of Science ®Google Scholar
• Díaz-Lagares C, Croca S, Sangle S, Vital EM, Catapano F, Martínez-Berriotxoa A, et al.; UK-BIOGEAS Registry. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev. 2012;11(5):357–64.
   PubMed Web of Science ®Google Scholar
• Weidenbusch M, Rommele C, Schrottle A, Anders HJ. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant. 2013;28(1):106–11.
   PubMed Web of Science ®Google Scholar
• Murray E, Perry M. Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol. 2010;29(7):707–16.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus. 2009;18(9):767–76.
   PubMed Web of Science ®Google Scholar
• Ready V, Jayne D, Close D, Isenberg D. B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res Ther. 2013;15(Suppl 1):S2.
   Web of Science ®Google Scholar
• Murphy G, Lisnevskaia L, Isenberg D. Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment. Lancet. 2013;382:809–18.
   PubMed Web of Science ®Google Scholar
• Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet. 2014;384:1878–88.
   PubMed Web of Science ®Google Scholar
• Pepper R, Griffith M, Kirwan C, Levy J, Taube D, Pusey C, et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant. 2009;24(12):3717–23.
   PubMed Web of Science ®Google Scholar
• Ezeonyeji A, Isenberg D. Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen. Rheumatology 2012;51(3):476–81.
   PubMed Web of Science ®Google Scholar
• Stone J, Merkel P, Spiera R, Seo P, Langford C, Hoffman G, et al. Rituximab versus Cyclophosphamide for ANCA-associated vasculitis. N Eng J Med. 2010;363(3):221–32.
   PubMed Web of Science ®Google Scholar
• Joly P, Mouquet H, Roujeau JC, D'lncan M, Gilbert D, Jacquot S, et al. A single cycle of rituximab for treatment of severe pemphigus. N Eng J Med. 2007;357(6):545–52.
   PubMed Web of Science ®Google Scholar
• Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei, K, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomized, placebo-controlled trial. Lancet 2014;384(9950):1273–81.
   PubMed Web of Science ®Google Scholar
• Takei T, Itabashi M, Moriyama T, Kojima C, Shiohira S, Shimizu A, et al. Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults. Nephrol Dial Transplant. 2013;28(5):1225–32.
   PubMed Web of Science ®Google Scholar
• Condon M, Ashby D, Pepper R, Cook H, Levy J, Griffith M, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013;72(8):1280–6.
   PubMed Web of Science ®Google Scholar
• Imperial College London. Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroid for Lupus Nephritis (RITUXILUP). NCT01773616. Available from: www.ClinicalTrials.gov.
   Google Scholar
• Houssiau FA, on behalf of European Working Party on Systemic Lupus Erythematosus Lupus Nephritis Trial Network. RING: rituximab for lupus nephritis with remission as a goal. NCT01673295. Available from: www.ClinicalTrials.gov.
   Google Scholar